Scarica l'app Stockscreener
6.48
0.93%
0.06
Dopo l'orario di chiusura:
6.47
-0.01
-0.15%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$6.42
Aprire:
$6.4
Volume 24 ore:
131.42K
Relative Volume:
0.60
Capitalizzazione di mercato:
$349.16M
Reddito:
-
Utile/perdita netta:
$-32.77M
Rapporto P/E:
-9.2797
EPS:
-0.6983
Flusso di cassa netto:
$-29.56M
1 W Prestazione:
-5.40%
1M Prestazione:
-16.71%
6M Prestazione:
-7.43%
1 anno Prestazione:
+63.64%
Intervallo 1D:
$6.20
$6.51
Intervallo di 1 settimana:
$6.10
$7.4699
Portata 52W:
$3.19
$10.42
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Nome
Diamedica Therapeutics Inc
Settore
Industria
Telefono
(763) 496-5454
Indirizzo
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Compare DMAC vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
6.48 | 349.16M | 0 | -32.77M | -29.56M | -0.6983 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-14 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-10-30 | Iniziato | TD Cowen | Buy |
| 2024-10-07 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-24 | Ripresa | Craig Hallum | Buy |
| 2023-06-22 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-04-09 | Iniziato | Oppenheimer | Outperform |
| 2021-02-17 | Iniziato | ROTH Capital | Buy |
| 2020-10-30 | Iniziato | Guggenheim | Buy |
| 2020-07-08 | Iniziato | Maxim Group | Buy |
| 2019-04-30 | Iniziato | Dougherty & Company | Buy |
| 2019-03-05 | Iniziato | Lake Street | Buy |
Mostra tutto
Diamedica Therapeutics Inc Borsa (DMAC) Ultime notizie
Q1 EPS Estimate for DiaMedica Therapeutics Raised by Analyst - MarketBeat
What is HC Wainwright’s Forecast for DMAC FY2029 Earnings? - Defense World
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Diamedica Therapeutics (DMAC), Elevance Health (ELV) and Oric Pharmaceuticals (ORIC) - The Globe and Mail
HC Wainwright Issues Pessimistic Estimate for DMAC Earnings - MarketBeat
Top Wall Street forecasters revamp DiaMedica Therapeutics expectations ahead of Q4 earnings - MSN
[ARS] DiaMedica Therapeutics Inc. SEC Filing - Stock Titan
Equity plan expansion at DiaMedica (NASDAQ: DMAC) adds 3.5M shares - Stock Titan
H.C. Wainwright reiterates DiaMedica stock rating on trial progress By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates DiaMedica stock rating on trial progress - Investing.com
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2025 Earnings Call Transcript - Insider Monkey
DiaMedica Therapeutics Furnishes 2025 Financial Results and Business Update - The Globe and Mail
DMAC Should I Buy - Intellectia AI
DiaMedica Therapeutics Inc (DMAC) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
DiaMedica Therapeutics Inc.Common Stock - FinancialContent
DiaMedica Therapeutics Reports 2025 Financial Results - National Today
DiaMedica reiterates plan for ReMEDy2 interim analysis in 2H 2026 as stroke trial approaches 70% of 200 patients - MSN
DiaMedica Therapeutics Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
DiaMedica Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: DiaMedica Therapeutics Q4 2025 shows liquidity boost By Investing.com - Investing.com South Africa
Earnings call transcript: DiaMedica Therapeutics Q4 2025 shows liquidity boost - Investing.com
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights - BioSpace
Loss Report: Is DiaMedica Therapeutics Inc a cyclical or defensive stockTrade Analysis Report & AI Optimized Trading Strategy Guides - baoquankhu1.vn
DiaMedica Therapeutics (DMAC) Strengthens Financial Position and Advances Clinical Programs - GuruFocus
Rising R&D widens loss as DiaMedica (NASDAQ: DMAC) funds DM199 - Stock Titan
DiaMedica Therapeutics (NASDAQ:DMAC) Issues Quarterly Earnings Results, Meets Expectations - MarketBeat
DiaMedica Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
DM199 pipeline: DiaMedica Therapeutics (NASDAQ: DMAC) targets stroke and preeclampsia - Stock Titan
Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings - Benzinga
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
DiaMedica Therapeutics Inc expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Price Action: Can DiaMedica Therapeutics Inc keep up with sector leadersRate Cut & Weekly Watchlist of Top Performers - baoquankhu1.vn
Can DiaMedica Therapeutics Inc keep up with sector leadersRate Cut & Weekly Watchlist of Top Performers - baoquankhu1.vn
DiaMedica Therapeutics (DMAC) Projected to Post Earnings on Tuesday - Defense World
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026 - weeklyvoice.com
User - The Chronicle-Journal
DiaMedica Therapeutics appoints Julie Krop as Chief Medical Officer - MSN
Market Review: How does DiaMedica Therapeutics Inc compare to its peers2026 Technical Patterns & Expert Verified Movement Alerts - baoquankhu1.vn
Cooperman Leon G Raises Position in DiaMedica Therapeutics, Inc. $DMAC - MarketBeat
Does DiaMedica Therapeutics (DMAC) Have the Potential to Rally 114.06% as Wall Street Analysts Expect? - MSN
DiaMedica receives Health Canada clearance for preeclampsia study - Investing.com Nigeria
Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Codexis (CDXS) and Diamedica Therapeutics (DMAC) - The Globe and Mail
What Makes DiaMedica Therapeutics, Inc. (DMAC) a Strong Momentum Stock: Buy Now? - msn.com
DiaMedica Therapeutics (DMAC) Expected to Announce Earnings on Monday - MarketBeat
Geopolitics Watch: Is DiaMedica Therapeutics Inc. stock attractive for ETFsQuarterly Profit Review & Daily Profit Focused Screening - Naître et grandir
DiaMedica Therapeutics raises capital via share offering - MSN
DiaMedica Therapeutics, Inc. $DMAC Shares Purchased by Paragon Associates & Paragon Associates II Joint Venture - MarketBeat
Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (CMPX), Diamedica Therapeutics (DMAC) and Veeva Systems (VEEV) - The Globe and Mail
DiaMedica receives Health Canada clearance for preeclampsia study By Investing.com - Investing.com South Africa
Sentiment Watch: Whats the fair value of AEV CL stockAnalyst Downgrade & Low Risk Investment Opportunities - baoquankhu1.vn
DiaMedica (DMAC) Gains Health Canada Approval for Preeclampsia T - GuruFocus
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia - The AI Journal
Diamedica Therapeutics Inc Azioni (DMAC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):